(1) Background: The advantage of using carbapenems over beta-lactam/beta-lactamase
inhibitor combinations in critically ill septic patients still remains a debated issue. We aimed …

(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections
caused by full-or multi-susceptible Enterobacterales and/or Pseudomonas aeruginosa in …

Objectives We utilized the database of the Defining Antibiotic Levels in Intensive care unit
patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and …

Background Several studies have indicated that commonly used piperacillin-tazobactam
(TZP) and meropenem (MEM) dosing regimens lead to suboptimal plasma concentrations …

Objective To determine the percentage of patients given standard doses of piperacillin/
tazobactam or meropenem by continuous infusion who achieved the target pharmacokinetic …

Background Healthcare-associated infections involving Gram-negative bacteria (GNB) with
difficult-to-treat resistance (DTR) phenotype are associated with impaired patient-centered …

Purpose Insufficient antimicrobial exposure is associated with worse outcomes in sepsis. We
evaluated whether therapeutic drug monitoring (TDM)-guided antibiotic therapy improves …

Abstract Background and Objectives Morbidity and mortality from serious infections are
common in intensive care units (ICUs). The appropriateness of the antibiotic treatment is …

Background We analyzed the attainment of early pharmacological targets of continuous
infusion meropenem and piperacillin/tazobactam and the use and effect of a real-time …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …